Novo Nordisk A/S Class B Overview
Novo Nordisk A/S Class B (NONOF) has a P/E ratio of 11.27, below the Healthcare sector average of 25.9.
Get informed when a big investor buys or sells
+ Follow11.27
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for NONOF is 11.27. That is below the Healthcare sector average of 25.9. Investors often review this figure alongside Novo Nordisk A/S Class B's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, NONOF currently prints 11.27 for P/E ratio, while the sector average sits near 25.9. That is roughly 56.5% below the sector mean. Large gaps often invite a closer look at Novo Nordisk A/S Class B's growth, margins, and balance sheet.
A P/E ratio of 11.27 for Novo Nordisk A/S Class B is not 'good' or 'bad' on its own. Compare it with the peer average (25.9) and with NONOF's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting NONOF's P/E ratio (11.27), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Novo Nordisk A/S Class B's P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
